title: Updates in Therapy for Advanced Melanoma.
abstract: Cutaneous melanoma is one of the most aggressive forms of skin cancer, and is correlated with a large proportion of skin cancer-related deaths. Therapy for cutaneous melanoma has advanced greatly through careful identification of therapeutic targets and the development of novel immunotherapeutic approaches. The identification of BRAF as well as other driver mutations, have allowed for a specialized approach to treatment. In addition, immune checkpoint inhibition has dramatically changed the treatment landscape over the past 5-10 years. The successful targeting of CTLA-4, as well as PD-1/PD-L1, has been translated into meaningful clinical benefit for patients, with multiple other potential agents in development. Systemic therapy for cutaneous melanoma is becoming more nuanced and often takes a multifaceted strategy. This review aims to discuss the benefits and limitations of current therapies in systemic melanoma treatment as well as areas of future development.
authors.affiliation: Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710, USA. bhavana.pendurthi@dm.duke.edu.
authors.forename: Bhavana P
authors.initials: BP
authors.lastname: Singh
authors.affiliation: Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710, USA. april.salama@dm.duke.edu.
authors.forename: April K S
authors.initials: AK
authors.lastname: Salama
keywords: BRAF; CTLA-4; MEK; PD-1; immunotherapy; melanoma; targeted therapy